175 related articles for article (PubMed ID: 12144580)
1. Effects of rabeprazole, 20 mg, or esomeprazole, 20 mg, on 24-h intragastric pH and serum gastrin in healthy subjects.
Warrington S; Baisley K; Boyce M; Tejura B; Morocutti A; Miller N
Aliment Pharmacol Ther; 2002 Jul; 16(7):1301-7. PubMed ID: 12144580
[TBL] [Abstract][Full Text] [Related]
2. Effect of esomeprazole and rabeprazole on intragastric pH in healthy Chinese: an open, randomized crossover trial.
Li ZS; Zhan XB; Xu GM; Cheng NN; Liao Z
J Gastroenterol Hepatol; 2007 Jun; 22(6):815-20. PubMed ID: 17565634
[TBL] [Abstract][Full Text] [Related]
3. Effects of single doses of rabeprazole 20 mg and esomeprazole 40 mg on 24-h intragastric pH in healthy subjects.
Warrington S; Baisley K; Dunn K; Boyce M; Morocutti A
Eur J Clin Pharmacol; 2006 Sep; 62(9):685-91. PubMed ID: 16850327
[TBL] [Abstract][Full Text] [Related]
4. A placebo-controlled trial to assess the effects of 8 days of dosing with rabeprazole versus omeprazole on 24-h intragastric acidity and plasma gastrin concentrations in young healthy male subjects.
Williams MP; Sercombe J; Hamilton MI; Pounder RE
Aliment Pharmacol Ther; 1998 Nov; 12(11):1079-89. PubMed ID: 9845397
[TBL] [Abstract][Full Text] [Related]
5. Combined analysis of three crossover clinical pharmacology studies of effects of rabeprazole and esomeprazole on 24-h intragastric pH in healthy volunteers.
Norris V; Baisley K; Dunn K; Warrington S; Morocutti A
Aliment Pharmacol Ther; 2007 Feb; 25(4):501-10. PubMed ID: 17270006
[TBL] [Abstract][Full Text] [Related]
6. [Comparative effectiveness of the antisecretory action of rabeprazole and esomeprazole in people with rapid metabolism of proton pump inhibitors].
Morozov SV; Tsodikova OM; Isakov VA; Gushchin AE; Shipulin GA
Eksp Klin Gastroenterol; 2003; (6):58-63, 154. PubMed ID: 15065530
[TBL] [Abstract][Full Text] [Related]
7. Esomeprazole 40 mg provides improved intragastric acid control as compared with lansoprazole 30 mg and rabeprazole 20 mg in healthy volunteers.
Wilder-Smith CH; Röhss K; Nilsson-Pieschl C; Junghard O; Nyman L
Digestion; 2003; 68(4):184-8. PubMed ID: 14691345
[TBL] [Abstract][Full Text] [Related]
8. A placebo-controlled study to assess the effects of 7-day dosing with 10, 20 and 40 mg rabeprazole on 24-h intragastric acidity and plasma gastrin in healthy male subjects.
Williams MP; Blanshard C; Millson C; Sercombe J; Pounder RE
Aliment Pharmacol Ther; 2000 Jun; 14(6):691-9. PubMed ID: 10848651
[TBL] [Abstract][Full Text] [Related]
9. Esomeprazole 40 mg provides more effective intragastric acid control than lansoprazole 30 mg, omeprazole 20 mg, pantoprazole 40 mg and rabeprazole 20 mg in patients with gastro-oesophageal reflux symptoms.
Röhss K; Lind T; Wilder-Smith C
Eur J Clin Pharmacol; 2004 Oct; 60(8):531-9. PubMed ID: 15349707
[TBL] [Abstract][Full Text] [Related]
10. Effects of rabeprazole, lansoprazole and omeprazole on intragastric pH in CYP2C19 extensive metabolizers.
Saitoh T; Fukushima Y; Otsuka H; Hirakawa J; Mori H; Asano T; Ishikawa T; Katsube T; Ogawa K; Ohkawa S
Aliment Pharmacol Ther; 2002 Oct; 16(10):1811-7. PubMed ID: 12269976
[TBL] [Abstract][Full Text] [Related]
11. A comparison of the acid-inhibitory effects of esomeprazole and rabeprazole in relation to pharmacokinetics and CYP2C19 polymorphism.
Hunfeld NG; Touw DJ; Mathot RA; van Schaik RH; Kuipers EJ
Aliment Pharmacol Ther; 2012 Apr; 35(7):810-8. PubMed ID: 22324425
[TBL] [Abstract][Full Text] [Related]
12. Intragastric acidity after switching from 5-day treatment with intravenous pantoprazole 40 mg/d to 5-day treatment with oral esomeprazole 40 mg/d or pantoprazole 40 mg/d: an open-label crossover study in healthy adult volunteers.
Miner PB; Tutuian R; Castell DO; Liu S; Sostek MB
Clin Ther; 2006 May; 28(5):725-33. PubMed ID: 16861094
[TBL] [Abstract][Full Text] [Related]
13. Gastric acid control with esomeprazole, lansoprazole, omeprazole, pantoprazole, and rabeprazole: a five-way crossover study.
Miner P; Katz PO; Chen Y; Sostek M
Am J Gastroenterol; 2003 Dec; 98(12):2616-20. PubMed ID: 14687806
[TBL] [Abstract][Full Text] [Related]
14. The effects of oral rabeprazole on endocrine and gastric secretory function in healthy volunteers.
Dammann HG; Burkhardt F; Wolf N
Aliment Pharmacol Ther; 1999 Sep; 13(9):1195-203. PubMed ID: 10468701
[TBL] [Abstract][Full Text] [Related]
15. Eradication of Helicobacter pylori increases nocturnal intragastric acidity during dosing with rabeprazole, omeprazole, lansoprazole and placebo.
Williams MP; Usselmann B; Chilton A; Sercombe J; Nwokolo CU; Pounder RE
Aliment Pharmacol Ther; 2003 Mar; 17(6):775-83. PubMed ID: 12641499
[TBL] [Abstract][Full Text] [Related]
16. CYP2C19 genotype status and intragastric pH during dosing with lansoprazole or rabeprazole.
Adachi K; Katsube T; Kawamura A; Takashima T; Yuki M; Amano K; Ishihara S; Fukuda R; Watanabe M; Kinoshita Y
Aliment Pharmacol Ther; 2000 Oct; 14(10):1259-66. PubMed ID: 11012469
[TBL] [Abstract][Full Text] [Related]
17. An open-label, parallel, multiple-dose study comparing the pharmacokinetics and gastric acid suppression of rabeprazole extended-release with esomeprazole 40 mg and rabeprazole delayed-release 20 mg in healthy volunteers.
Morelli G; Chen H; Rossiter G; Rege B; Lu Y
Aliment Pharmacol Ther; 2011 Apr; 33(7):845-54. PubMed ID: 21272047
[TBL] [Abstract][Full Text] [Related]
18. Effect of rabeprazole (E3810), a novel proton pump inhibitor, on intragastric pH in healthy volunteers.
Hongo M; Kimpara T; Moriyama S; Ohara S; Sone S; Tamura T; Asaki S; Toyota T
Tohoku J Exp Med; 1998 Sep; 186(1):43-50. PubMed ID: 9915106
[TBL] [Abstract][Full Text] [Related]
19. An ascending single-dose safety and tolerance study of an oral formulation of rabeprazole (E3810).
Lew EA; Barbuti RC; Kovacs TO; Sytnic B; Humphries TJ; Walsh JH
Aliment Pharmacol Ther; 1998 Jul; 12(7):667-72. PubMed ID: 9701531
[TBL] [Abstract][Full Text] [Related]
20. Pharmacodynamic effects of single doses of rabeprazole 20 mg and pantoprazole 40 mg in patients with GERD and nocturnal heartburn.
Warrington S; Baisley K; Lee D; Lomax K; Delemos B; Boyce M; Morocutti A
Aliment Pharmacol Ther; 2007 Feb; 25(4):511-7. PubMed ID: 17270007
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
